Integrating primary care of chronic respiratory disease, cardiovascular disease and diabetes in Brazil: Practical Approach to Care Kit (PACK Brazil): study protocol for randomised controlled trials

Abstract

Background

Multimorbidity is increasing common in Brazilian adults. Comorbid chronic lung disease, cardiovascular disease and diabetes are often inaccurately diagnosed or ineffectively treated. The Global Alliance against Chronic Respiratory Diseases (GARD) aims to strengthen health systems to prevent and control non-communicable diseases through primary health care. The Practical Approach to Care Kit (PACK Adult) is a clinical decision support tool that provides evidence-supported algorithmic guidelines for screening, diagnosis and treatment of chronic diseases, and is widely used in South Africa. It was adapted for Brazil by family physicians in the Florianopolis City Health Department, which trains clinic doctors and nurses to use it.

Methods

Effectiveness of PACK Adult training will be evaluated in two pragmatic cluster randomised trials, one enrolling adults with chronic lower respiratory diseases and the other enrolling adults with cardiovascular disease or diabetes. Forty-eight municipal clinics in Florianopolis were randomly allocated to intervention or control arms. In intervention arm clinics, doctors and nurses will receive educational outreach training and the PACK Adult clinical decision support tool. In control arm clinics, doctors and nurses will receive only the tool. Trial outcomes will be measured using patients’ electronic medical records during 12 months after completion of basic training. Primary outcomes for the respiratory trial are appropriate prescribing, spirometry and diagnosis rates. Primary outcomes for the cardiovascular trial are testing for cardiovascular risk and diabetes, and systolic blood pressure. Educational outreach to primary care professionals could improve respiratory, cardiovascular and diabetes care in Brazil.

Trial registration

NCT02786030 and NCT02795910 (https://clinicaltrials.gov/)

Introduction

Chronic non-communicable diseases (NCDs) place a heavy burden on populations and health services in Brazil and other middle-income countries (1). In 2016 NCDs caused about 76% of all deaths in Brazil (2). While it is necessary to prevent these diseases by tackling causes such as smoking, diet, and physical inactivity, primary health care is important for identifying NCDs early and optimising management. The Global Alliance against Chronic Respiratory Diseases (GARD) aims to prevent and reduce the burden of chronic respiratory disease (CRD) in low, middle and high-income countries through multisectoral actions (3). GARD strategy complements global strategies to prevent and control other NCDs such as cardiovascular disease (CVD), diabetes and cancer (3). Since GARD was launched in Brazil in 2006 there have been several advances towards controlling CRD, including strengthening the capacity of doctors and nurses to manage CRD in primary care (4).

The prevalence of NCD multimorbidity in Brazil is high (5,6), and will keep increasing as the population ages. Multimorbidity challenges primary health care professionals to consider, diagnose and treat additional diseases in patients who are already being treated for other chronic conditions. Brazil’s Family Health Programme provides a good base for developing, evaluating and upscaling initiatives to address NCDs, as it is a primary care system providing free continuing care in health centres, staffed by doctors, nurses and other health professionals in municipalities through the country. Established in 1998, by 2010 it had expanded to cover 98 million people and 85% of Brazil’s municipalities (5). This paper reports on plans to evaluate the effectiveness of a new way of tackling these problems in Brazilian primary care.

Better primary care can improve chronic disease outcomes

CRD was identified as one of four priority disease areas by the UN General Assembly of 2012, which urged governments to provide all people with access to affordable care (7). Asthma and chronic obstructive pulmonary disease (COPD) account for most morbidity and mortality attributable to CRDs (8,9). Low and middle-income countries carry a heavy CRD burden, but can greatly reduce hospitalizations and deaths from asthma and COPD by improved access to care and appropriate treatment. The national database of the Ministry of Health of Brazil shows that, over 10 years, municipalities that provided free inhaled corticosteroids (ICSs) for asthma had considerably higher odds of reducing hospital admissions and deaths from asthma than those that did not (10). Programmes to improve asthma care in the Brazilian cities of Salvador and Londrina, which included physician education, and free ICSs and long acting beta₂ agonists, resulted in large reductions in hospital admissions (11,12).

CVD is the leading cause of death in Brazil, even though age standardised death rates have decreased over the past 20 years (1). Expansion of the Family Health Programme was associated with about 20% reduction in mortality from heart and cerebrovascular disease from 2000 to 2009, showing the potential for primary care to reduce CVD burden (13). Although diabetes is less common, diabetes mortality has not decreased (1), and diabetes is often poorly controlled in Brazilian primary care (14). Diabetes often co-exists with other cardiovascular risk factors and disease, and integrated management of all CVD risks is needed. Hypertension is an especially important risk factor for diabetes, cardiovascular and cerebrovascular disease. As with CRD, these studies also show that good primary care can improve population health, but that integrated chronic disease management is still needed (10-12).

Implementing evidence-based chronic disease management

The Knowledge Translation Unit (KTU) of the University of Cape Town Lung Institute has been working since 2000 to strengthen primary health care in low and middle-income countries. It has developed several models for improving access to care, promoting early diagnosis and increasing access to evidence-based treatment for patients with priority conditions including common chronic diseases (15). To improve access to care, it has focussed on strengthening primary care services, encouraging evidence-based prescription policies and a clinical team approach, and, where possible and appropriate, task sharing with nurses, pharmacists and other staff. To improve capacity and quality of care it developed clinical decision support tools (CDST) and a training programme. Over-stretched clinicians often feel ill-equipped to deal with NCDs in primary care facilities, confused by often contradictory disease-specific guidelines. They can be empowered if provided with CDSTs that are localized to match their practice setting, scope of practice, resources and policies of the service in which they work, and to be evidence-based and up to date. KTU’s approach to training conforms to modern adult learning methods: interactive, case-based, and continuous, and offered by a trusted trainer on-site and in-service (16,17). This form of integrated care, using standardised diagnostic and treatment algorithms, is a recognized method for improving case detection, diagnosis and management, other examples being the WHO’s Integrated Management of Childhood Illness (IMCI) (18) and Package of Essential Non-Communicable Disease Interventions (WHO PEN) (19).

KTU first examined problems with diagnosis of asthma and COPD in South African primary care in the absence of routinely available spirometry (15,20). It then implemented a South African version of WHO’s Practical Approach to Lung Health (21), then expanded incrementally, to include sexually transmitted diseases and HIV infection (22), nurse-led antiretroviral treatment (23), and CVDs, diabetes, mental health and women’s health (24). Each version of the KTU tools has been evaluated in pragmatic randomized trials, in South Africa (21-24) and as a case study in Malawi (25). Over 250,000 copies of the CDSTs have been distributed in South Africa (where it is known currently as Adult Primary Care), and customized versions provided for Malawi, Botswana, Mexico City, Nigeria and Ethiopia. Globally, this programme is known as the Practical Approach to Care Kit (PACK) and is being spread through a non-profit partnership with the BMJ Publishing Group whose Knowledge Centre is responsible for developing more comprehensive clinical decision support mainly for high income country settings (26).

Development and implementation of PACK Adult in Brazil

PACK Adult in Brazil is the first localisation of PACK Global for adults led by an in-country team with mentorship provided by the KTU. Previously localisations outside of South Africa were either produced with intensive input from the KTU (Malawi, Botswana), or conducted independently (Mexico City). Work on PACK Brazil began in 2014 when the KTU entered an agreement with the City Health Department of Florianopolis, and BMJ Publishing Group to test a new mentorship model of spreading the PACK Global programme. Florianopolis is typical of a middle-income country urban setting with socioeconomic and health inequalities in which, despite good primary care coverage by official indicators, there are problems with accessibility to health care (only about half of the population use state-funded Family Health Programme clinics each year). Residents are registered with a local municipal primary care practice, which provides free medicines, while 44% of the population also has some health insurance. City Health Department doctors and other staff localised the PACK Adult content, ensuring compliance with Brazilian clinical protocols and practice, and translated it into Brazilian Portuguese. The training programme was based on South African PACK training, and revised with case studies and key messages localised to Brazilian priorities. The effectiveness of the training will be evaluated using the methods reported in this paper.

Methods

Objective

To determine the effectiveness of PACK Adult training with PACK CDST compared to passive dissemination of PACK CDST on the process of care and clinical outcomes for people with CRD, CVD or diabetes in primary care.

Hypothesis

PACK Adult training to use the CDST will increase investigations and diagnoses of CRD, CVD and diabetes; increase prescription of effective treatments; and improve health outcomes, compared to provision of a CDST without training.

Design

Pragmatic, parallel-group, superiority cluster randomised trial (27). All municipal clinics in Florianopolis were eligible for inclusion in the trial. However, 48 of all 49 municipal primary care clinics will be randomised to intervention or control groups (only one small clinic, with 600 registered patients, will be excluded so as to have equal numbers of clinics in each arm). Outcomes will be recorded at baseline and during 12 months’ follow-up (Figure 1).

Figure 1.

Study design and activities over time.

Location

The trial will be conducted in the city of Florianopolis, Brazil.

Random allocation

Clinics will be stratified by size (numbers of patient attendances during 2015, and numbers of doctor-nurse teams) and socio-economic status of the communities they serve, and randomly allocated to intervention and control arms in a 1:1 ratio using N-Query Advisor by C Lombard before the intervention begins using a wait list control design. Training in control clinics will begin after follow up ends.

Blinding

Blinding of health professionals is not possible because of the nature of the intervention. Outcomes will be recorded without patient input so blinding of patient is not necessary. However, in practice patients will not be informed whether training had been delivered in their clinics or not.

Study populations

Eligible patients will be identified using International Classification of Disease (ICD-10) diagnostic codes in primary care electronic medical records (EMRs) of each clinic visit, in a consolidated municipal database. Eligibility criteria are as follows.

CRD trial

All patients aged 18 years and over in March 2017 who attend a clinic during the first year of the trial, with either a clinical diagnosis of obstructive lung disease (ICD-10 codes 40-47) recorded in EMRs since January 1st 2010 (when EMRs began, for estimation of asthma and COPD scores), or who attend a clinic for any reason during the year of follow-up (for estimation of rates or new asthma and COPD diagnosis).

CVD and diabetes trial

All patients aged 35 years and over in March 2017 and with a diagnosis of hypertension (ICD-10 I10-I15), ischaemic heart disease (ICD-10 I20-I25), heart failure (ICD-10 I50), cerebrovascular disease (ICD-10 I60-I69), or diabetes mellitus (ICD-10 E10-E14, that is, including type 1 and type 2 diabetes) ever recorded since January 1st 2010, and who attend a participating clinic for any reason during the first year of the trial.

For both trials, the first year of the trial is defined as 1 April 2017 to 31 March 2018, and the baseline year is defined as 1 April 2016 to 31 March 2017.

Intervention group clinics (28)

Primary care doctors and nurses will get outreach education and copies of the PACK Adult CDST. The CDST is a printed book which is also available in electronic form. Staff training will comprise educational outreach sessions, using local practitioners (doctors and nurses) as trainers. Educational outreach training sessions are brief personal visits to health professionals at their place of practice. The training will use a cascade model, with four master trainers training and supporting twenty facility trainers who will then deliver the on-site sessions to the 24 intervention clinics. The facility trainers will be professionals recognised as clinical leaders by the staff and work as clinical mentors, enhancing knowledge exchange between staff and facilitating implementation of the PACK strategy. They will work in doctor/nurse pairs to train small doctor/nurse groups in the facility during 12 weekly sessions covering the first module of guideline content—including CRDs, CVD, and diabetes. The focus of the training is the approach to using the CDST in managing a variety of patients, and highlights key messages about the identification of the conditions, their appropriate management and secondary level referral. After an initial intensive overview of CDST and how to use it, the rest of the CDST content will be covered in monthly on-site sessions. Continual clinical support will be provided by the family physician who led the localisation of the CDST (R Zonta). Electronic discussions will be posted on a web discussion site and accessed by all trainers and trainees. Individuals’ participation in training sessions will be monitored to assess intervention coverage.

Control group clinics

Primary care doctors and nurses will get copies of the PACK CDST, without training, assuming that passive dissemination of printed materials alone have negligible effects on clinician behaviour (29).

Trial outcomes

The outcomes include indicators of health status, and of health care processes prioritised in the CDST and training and involving treatments and tests that are available in the trial clinics. Because the needs of different patients differ, it is not possible to assess appropriateness of interventions and treatment in individual patients. Rather, within each category of disease, we have selected processes which, when applied to groups of patients, result in favourable health outcomes. The composite outcomes reflect a variety of appropriate clinical responses for that category of patient. Thus, we will be able to detect changes and differences in the frequency of these selected composite process outcomes in the study population.

CRD trial

Primary outcomes

The three primary outcomes selected for this study represent key health care processes that have been shown in Brazil and other countries to be associated with better health outcomes in patients with asthma and COPD, reflect the quality and intensity of respiratory care, and are based on actions recommended in the CDST (30,31). The use of composite scores as primary outcomes is similar to WHO’s Multi Country Evaluation of IMCI (32,33).

1. For patients with asthma the composite score will comprise points awarded for: (I) a first prescription of an ICS or ICS+ long-acting bronchodilator [long-acting beta₂ agonist (LABA)] combination, or a change in prescription, stepping up from short-acting bronchodilator [short-acting beta₂ agonist (SABA)] to ICS or from ICS to long-acting bronchodilator (LABA) + ICS combination; or stepping down from LABA + ICS to ICS, or from ICS to SABA (scoring one point if at least one of these occurs); and (II) request for spirometry (1 point). The composite score will be the sum of these points, and will thus range from 0 to 2;

2. For patients with COPD the composite score will comprise points awarded for: (I) a first prescription of SABA, ICS, or ICS + LABA; or a change in prescription, stepping up from SABA to LABA or LABA to ICS + LABA, or stepping down from LABA + ICS to LABA, or from LABA to SABA (scoring one point if at least one of these occurs) and (II) request for spirometry (1 point). The composite score will be the sum of these, and will thus also range from 0 to 2;

3. At clinic level, the incidence rate of new diagnoses of asthma or COPD among all patients who use each clinic for the duration of the trial. This endpoint addresses the problem of under-diagnosis of these conditions which the CDST aims to address.

Secondary outcomes

At clinic level: hospital admission rate for asthma in each clinic; hospital admission rate for COPD in each clinic and, at patient level: CVD disease (ICD-10 I00-I99) diagnosed for the first time; diabetes mellitus (ICD-10 E10-E14) diagnosed for the first time; medications to support tobacco cessation (nicotine replacement therapy, nortriptyline, or bupropion prescribed); blood pressure recorded, or cholesterol, glucose, or electrocardiogram tests recorded; depression (ICD-10 F32-F34) diagnosed for the first time; medication for depression (tricyclic and related antidepressants, selective serotonin re-uptake inhibitors, and monoamine oxidase inhibitors) prescribed for the first time; death from any cause and from respiratory disease. The outcomes relating to CVD, diabetes and depression indicate increased awareness and management of comorbidity in patients with CRD.

CVD and diabetes trial

Primary outcomes

The two primary outcomes indicate assessment of cardiovascular risk and comorbidity, and control of blood pressure which is relevant to all CVD and diabetes.

1. Number of participants in whom at least one of the following tests was recorded: body mass index, plasma glucose, glycated haemoglobin (HbA1c), serum cholesterol, electrocardiogram;

2. In participants with systolic blood pressure (SBP) >140 mmHg recorded during 12 months before start of follow up, average SBP recorded.

Secondary outcomes

These outcomes are indicators of more active clinical management or health outcome. Outcomes relating to depression indicate increased awareness and management of comorbid depression. Outcomes measured at patient level will be: number of tests for cardiovascular and diabetes risk factors (body mass index, glucose tested, serum cholesterol tested, electrocardiogram, chest X-ray); mean diastolic blood pressure (DBP); statin prescribed for the first time; statin dose changed; depression diagnosed for the first time; antidepressant prescribed; heart failure diagnosed for the first time; ischemic heart disease diagnosed for the first time; cerebrovascular disease diagnosed for the first time; in participants with a diagnosis of heart failure, new prescriptions for diuretic, angiotensin-converting enzyme (ACE) inhibitor or beta blocker; in participants with a diagnosis of hypertension, prescription for increased dose of diuretic, ACE inhibitor, calcium channel blocker or beta blocker; in participants with a diagnosis of ischemic heart disease, new prescription of ACE inhibitor, nitrate, beta blocker, ACE inhibitor or angiotensin II receptor antagonist; in participants with diabetes, change in prescription from oral diabetes medication to insulin; specialist referral to pulmonology, cardiology or endocrinology; in participants with SBP >140 mmHg or DBP >90 mmHg recorded during 12 months before enrolment, SBP ≤140 mmHg and DBP ≤90 mmHg. Outcomes measured at clinic level will be: hospital admission rates for CVD or diabetes; rate of death from any cause and from CVD or diabetes.

Data collection and management

Quantitative data on outcomes and baseline variables will be extracted from the municipal health department’s EMRs which include every clinic. Clinical data (including coded symptoms, ICD-10 coded diagnoses, prescriptions and test requests) are entered during each consultation by a doctor or nurse, and linked at city, practice and patient levels. The database is actively managed and regularly interrogated by the lead doctor (MP de Andrade). Aggregate hospital admission and mortality data are recorded at clinic level and cannot yet be linked to individual patients; they will be monitored as indicators of potential adverse effects of the intervention. A data monitoring committee was not needed because the trial used only routinely collected EMRs and aggregated data which the investigators had critically evaluated for the 7 years before follow-up began. The principal investigators and City Health Department doctors will have access to the data.

Sample size and power

CRD trial

The following estimates are based on analysis of EMRs from participating clinics in 2016. Numbers eventually recruited into the trial may differ as they will depend on clinic visits and diagnoses recorded during the baseline year and year of follow-up. About 2,900 eligible patients with a diagnosis of asthma and 1,400 with COPD were recorded as visiting participating clinics during 2016. That is, in each clinic there will be an average of about 60 eligible patients with asthma and 28 with COPD. The mean outcome scores per patient were 0.43 [SD 0.50, intracluster correlation coefficient (ICC) 0.033] for asthma and 0.42 (SD 0.48, ICC 0.055) for COPD. The trial will therefore have 90% power to detect a 26% increase in mean asthma score (0.54 vs. 0.43), and a 33% increase in mean COPD score (0.56 vs. 0.42), with 5% significance. At clinic level, the mean annual rate of new diagnoses or asthma or COPD was 1.1 (SD 0.46) per 100 patients aged ≥18 attending for any reason, providing 85% power to detect a 36% increase in rates of diagnosis (1.5 vs. 1.1 per 100/year). With Bonferroni correction to the significance level, to account for having three primary outcomes (P=0.05/3=0.017), the power to detect these differences as significant is 84%, 82% and 73%, respectively.

CVD and diabetes trial

There were 15,600 eligible patients with SBP >140 mmHg recorded in 2016, that is, an average of about 325 eligible patients with the primary outcome recorded in each clinic. In 2016, mean SBP in these patients was 138 (SD 17) mmHg, ICC =0.015. This provides 96% power to detect a difference in mean SBP of 2.5 mmHg or more between trial arms, with 5% significance. Of about 28,550 eligible patients (595 per clinic), 49% had glucose, cholesterol, ECG or chest X-ray tested during 2016, ICC =0.069. This provides 92% power to detect a 12% difference (49% vs. 61%) in the proportion who have at least one of these tests, with 5% significance. With a 2.5% significance level to account for having two primary outcomes (P=0.05/2=0.025), for each endpoint the power to detect these differences as significant is 93% and 87%, respectively.

Statistical analysis

We will compare primary and secondary trial outcomes between intervention and control clinics, using multilevel random effect regression models to adjust for the cluster randomised design in individual level analyses, and for baseline covariates if they are unbalanced. Analyses of asthma and COPD scores and SBP, as primary outcomes, will be at individual participant level. Analyses of rates of asthma and COPD diagnosis, hospital admission and mortality will be at clinic level. All other analyses of secondary outcomes will be at individual level. Analysis will be by intention to treat. Analyses of SBP as primary outcome will use the mean of all SBPs recorded during 12 months of follow-up, and baseline covariates will include mean SBP recorded during 12 months before the start of follow-up. Subgroup analyses will investigate whether intervention effects are modified by clinic size, doctor-nurse ratio, gender, age, disease and area deprivation level, by adding interaction variables to the regression models. Secondary analyses will explore potential time trends in effects within the year of follow-up, and also for 12 months after that year (when control clinics will receive the intervention). There will be no interim analyses or stopping rules.

Ethics and research governance

Ethical guidance on cluster randomized trials and on use of medical records for research will be followed, as follows (34,35). Professionals and managers in each clinic have consented to their clinic taking part in the trial. The trials will be based on EMRs without patient contact and obtaining consent from each individual will not be feasible. It is not feasible to obtain patients’ consent to be randomised to intervention or control arms, because randomisation and delivery of the intervention will be at clinic level. Intervention- and control-type care cannot be provided to different patients within the same clinic because of the practicalities of clinic staffing, training and management (28). Even if patients preferred doctor- or nurse-led care or did not consent to take part in the trial, they would thus still necessarily receive the type of care that the clinic was allocated to provide.

Patients will not be asked for consent for their EMRs to be used for this research because it is not feasible without greatly increasing research costs. However, we will adhere to the ethical principles for use of medical records without patients’ consent (29), as follows. The research has a clear public benefit. We have obtained approval for the study from the lead doctors and nurses managing the programme. Use of the data for research will not influence decisions about individuals’ care. Only health department data managers have access to personal identifiers. Data with patient identifiers will be held by the Florianopolis City Health Department, and anonymised unlinked data will be securely stored at the University of East Anglia and the University of Cape Town.

Discussion

These randomised trials will evaluate the effects of a complex educational and health systems intervention aimed at primary care professionals and intended to improve clinical practice and health outcomes among adults with respiratory disease, CVD or diabetes. The trial focuses in particular on diagnosis of neglected and comorbid conditions, on initiation and modification of treatment, and blood pressure control which is clinically important for all CVDs and diabetes. Increased provision of preventive treatment for CRD, and better management of vascular risk in people with CVDs and diabetes, are well recognised as priorities for middle income countries like Brazil. However, achieving these aims can be difficult. Several trials have attempted to improve the management of multimorbidity in primary care in high income countries, with mixed results (36), and others are under way (37-40), but evidence from middle income countries is lacking. It will be valuable to know whether this type of intervention, which has been shown to be effective in South Africa, will be effective in Brazil.

Randomised trials of complex interventions in real-world health systems to address several diseases together face methodological challenges. Specifying one primary outcome may be inappropriate if one is equally concerned about more than one health condition, and if one aims to change several aspects of professional practice. Professional educational interventions covering a range of conditions delivered to many facilities and to diverse professionals as part of their routine practice may have small effects, some of which may take years to improve health outcomes. To overcome these challenges, such trials may need large samples, long follow-up and major research funding, which can be difficult to raise in settings where they are most needed.

This protocol aims to address these challenges. It proposes two simultaneous trials, with each covering a group of closely related conditions, having more than one primary outcome and with adequate statistical power. It is noteworthy that lowering the statistical significance level to account for more than one primary outcome does not greatly reduce power. We are able to obtain large samples, especially for the CVD and diabetes trial, by including all eligible municipal clinic users in a medium-sized city, using EMRs for enrolment and outcome measurement. In addition to assessing the biological effects of the intervention on blood pressure, which is highly important to all of the cardiovascular conditions and diabetes, the trials will be able assess evidence of intensification of investigation and treatment of these important but often neglected conditions. Inclusion of a whole Brazilian city enhances the generalisability of the trials.

The proposed trials have limitations, partly due to the limitations of the EMR data and of other resources. Although they have good quality data on diagnoses, investigations, prescriptions and referrals, which accurately indicate clinical practice, the EMRs have limited data on health outcomes at individual patient level. Relevant outcomes such as symptom severity, blood chemistry, lung function, and quality of life are not available. However, clinic level disease-specific rates of hospital admissions and deaths are recorded and are included in the trials’ secondary outcomes. Although the cluster randomisation design was intended to avoid contamination between intervention and control clinics, contamination is still possible, for example by patients switching between clinics, by staff transfers between clinics, and by communication between professionals working in intervention and control clinics. We will analyse the EMRs to assess the risk of contamination by patient switches and staff transfers. Lastly, although the study population includes all public sector primary clinics in the city, it excludes private, specialist and inpatient care. Inclusion of these services would require a much more complex intervention which was not feasible with available resources and local support.

In summary, routine use of EMRs is increasing rapidly in Brazilian primary care, and this protocol shows how they could be used more widely to evaluate system-wide interventions. If shown to be effective, this approach to improving the quality of care could be implemented more widely in Brazil and in other low and middle-income countries. The most direct relevance, however, will be towards finding practical ways of improving clinical management and health outcomes of adults with respiratory and CVD and diabetes in Brazilian public sector primary care.

Ethical Statement: The protocol was approved by the Research Ethics Committee of the Federal University of Santa Catarina (approval number: 1.539.125). Permission to carry out the trial was provided by the Florianopolis City Health Department. Patients will not be asked to provide consent to participate, for the reasons discussed in Ethics and research governance. Participation in the study will not affect patients’ future management.